Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC
Key Points
- MARIPOSA (amivantamab plus lazertinib) demonstrated superior progression-free survival compared with osimertinib alone, especially in high-risk central nervous system (CNS) disease.
- Shared decision-making and proactive toxicity management empower patients to adhere to complex regimens.
- Stereotactic radiosurgery (SRS) remains a viable option for resistant disease, but delaying radiation allows for years of higher-quality survival.
Intensification Therapy and CNS Considerations in EGFR-Mutant Non–Small Cell Lung Cancer
In EGFR-mutant non–small cell lung cancer (NSCLC) with CNS involvement, optimizing therapy requires careful consideration of both disease control and patient quality of life. Chinmay Jani, MD, of the University of Miami, and Luis Raez, MD, FACP, FCCP, FASCO, of Memorial Healthcare System, discussed strategies for intensification therapy versus monotherapy in patients with brain metastases.
Dr. Raez emphasized that current data from the MARIPOSA study supports combination therapy (amivantamab plus lazertinib) as the standard of care. He highlighted the importance of empowering patients with education about treatment options, expected adverse effects, and toxicity management, particularly for skin and nail toxicities associated with amivantamab.
CNS Metastases: Targeted Therapy Before Radiation
Historically, many patients with brain metastases received whole-brain radiation, which is associated with cognitive decline and reduced quality of life. Dr. Raez said that targeted therapies such as amivantamab now demonstrate CNS penetration, allowing for effective control of brain metastases while delaying or avoiding radiation. SRS remains an option for resistant disease or emergency cases, but its timing can now be strategically delayed to preserve quality of life.